Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Anand Rathi Report: India Pharma - Healthy growth in Dec'22; volumes slow down

Posted On: 2023-01-11 13:38:46 (Time Zone: IST)


Key Highlights:

The Dec'22 IPM grew 10.5%, primarily driven by price increases (6.8 percentage points), followed by new products (2.2 ppts) and volumes (1.4 ppts). On a MAT basis, the IPM grew 7.7%, primarily driven by price increases (6 ppts), followed by new products (1.7 ppts). Therapies such as respiratories (up 19%), anti infectives (15%) and VMN (12%) grew despite high bases. Cardiac, GI, derma and neuro/CNS therapies grew 7-8%. Acute therapies grew 13%; chronic and sub-chronic therapies, 8% and 10% respectively. Of MNCs, barring Abbott, AstraZeneca and GSK, all others undershot the IPM. Alembic and Alkem grew 16% each, while Cipla and Eris grew 14%-16%. Ipca and Lupin underperformed the IPM.

Mixed performance of domestic companies. On a low base, Natco recorded the highest growth (69%). Alembic and Alkem each grew 16%, while Cipla and Eris grew 14%-16%. JB Chemicals and Torrent's performances paralleled that of the IPM. Other companies such as Indoco, Dr Reddy's and Zydus grew 8-9.5%. Companies that undershot the IPM growth are Ipca (declining 3.4%), Lupin (2%), Ajanta (5%) and Sun (6%).

Spark missing for MNC pharmas. Barring Abbott (up 13%), AstraZeneca (12%) and GSK (9.5%), all others underperformed the IPM. Companies such as Sanofi and Pfizer grew a mere 1-2%.

Stellar growth for respiratory and anti-infective therapies. Respiratory therapies grew 19%, followed by anti infectives (15%) and VMN (12%). Cardiac, GI, derma and neuro/CNS therapies grew 7-8%, while anti-diabetes grew a mere 4%, as volumes of older molecules declined significantly, partially offset by increased demand for new products. Other therapies such as gynaecology, anti-neoplastics, ophthalmology, hormones and urology grew a healthy 11-17%.

Our view. A ramp-up has been seen across therapies such as respiratories, anti infectives and VMN (similar trends last seen during peak Covid times). In Dec, demand in acute therapies rose. Other therapies such as gynaecology, anti-neoplastics, ophthalmology, hormones and urology also picked up traction. Despite the high bases, we believe price hikes should aid decent growth for acute therapies, while the volume growth momentum in chronic therapies would continue to do well. We maintain our positive view on chronic therapy-focused companies such as Abbott, Ajanta Cipla, JB Chemicals, Eris and Torrent Pharma.


Click here to send ur comments or to feedback@equitybulls.com

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

CRISIL Ratings: Agrochemicals sector to see 7-9% growth amid modest exports

SBI Capital Markets: RBI Monetary Policy Dec'24 - RBI faces arduous task of managing all dynamics: Liquidity, Currency, Growth and Inflation

SBICAPS Monthly Ecocapsule Dec'24 : FY25 - A TALE OF TWO HALVES OR ONE OF FULL DESPAIR? - Executive Summary

CRISIL Ratings: Revenue growth of organised luggage makers to halve to 8-10%

CRISIL Ratings - Cement demand to grow at a moderate pace of 7-8% this fiscal

CRISIL Ratings: For small finance banks, RoA to dip ~40 bps this fiscal

Securitisation volumes witness strong growth; likely to reach ~Rs. 60,000 crore in Q2 FY2025: ICRA

CRISIL Ratings: Operating losses of state discoms to stay high despite 15-20% dip

CRISIL Ratings: Tamil Nadu garment exporters to see 8-10% revenue growth

CRISIL MI&A: Inflated natural rubber prices to puncture tyre maker margins

Infrastructure bond issuances by public sector banks to drive banks' bond issuances to an all-time high in FY2025: ICRA

CRISIL Ratings: Apparel retailers to stitch 8-10% growth with festivals, fast fashion

CRISIL Ratings: For ARCs, rising power consumption to boost recoveries from stressed operational thermal plants

Views of ICAI on SA 600 vs ISA 600

CRISIL Ratings: Wagon makers set to roll in ~20% revenue growth this fiscal

CRISIL Ratings: Basmati industry to see revenue grow ~4% on a high base this fiscal

CRISIL: Pharmaceutical sector set for 8-10% revenue growth this fiscal

CRISIL Ratings: Flexible packaging players' credit profiles to stay subdued this fiscal

Industry credit expected to grow over 12 per cent: FICCI-IBA Bankers' Survey

CRISIL Ratings: Decadal-low duty to push gold jewellery retailers' revenues up by 22-25%

CRISIL Ratings: Education loan AUM of NBFCs to top Rs 60,000 crore this fiscal

Evolving asset quality risks to impact growth and profitability of microfinance: ICRA

Near-term Consolidation; Focus Remains on Style & Sector Rotation - Axis Securities

CRISIL Ratings: Paper packaging volume to grow, but profitability to plumb lows

CRISIL MI&A: Corporate revenue growth likely moderated to 5-7% in April-June, the slowest in 15 quarters

CRISIL Ratings: Revenue growth of auto dealers to enter the slow lane this fiscal

Declining liquidity coverage ratios to slow down credit growth for banks: ICRA

CRISIL Ratings: Road developers to see slower revenue growth of 5-7% next fiscal

CRISIL Ratings: Small finance banks to grow advances 25-27% this fiscal

Global monetary easing to pick up pace - Puneet Pal, Head-Fixed Income, PGIM India Mutual Fund

Kotak Institutional Equities: Strategy: 1QFY25: Converging trends

CRISIL Ratings: Cement makers line up ~Rs 1.25 lakh crore capex over fiscals 2025-27

CRISIL Ratings: Urea import dependency to fall to 10-15% from this fiscal

CRISIL Ratings: 20% ethanol blending goal means more sugarcane utilisation

Kotak Institutional Equities: Automobiles & Components: 1QFY25 review: Steady quarter; demand outlook weakening

CRISIL MI&A: Macroeconomics First Cut - Goods exports fall, services soften

Kotak Institutional Equities: Consumer: 1QFY25 review- Uptick in staples, continued weakness in discretionary

CRISIL Ratings: Despite cash disbursement restriction gold-loan NBFCs shine

SBICAPS Report - The Green Pill: Labelled Bond Issuances, ESG Indices, Global Sustainable Funds

We expect the 10 yr benchmark bond yield to keep drifting lower gradually - PGIM India Mutual Fund

Strategy: Faith, froth and fundamentals by Kotak Institutional Equities

Earnings growth should be the key driver of returns hereon - Vinay Paharia - CIO, PGIM India Mutual Fund

IT Services: ERD services: Auto pulse-challenges ahead - Kotak Institutional Equities

Banks, Diversified Financials : Strong on expected lines across BFSI - Quarterly Review - Kotak Institutional Equities

Metals & Mining: SC ruling-empowers the states; marginal negative impact - Kotak Institutional Equities

CRISIL Ratings: Revised deposit norms unlikely to be onerous for HFCs

CRISIL Ratings: 6 gigawatt renewable energy storage to be added by fiscal 2028

CRISIL Ratings: Thermal share in power generation to dip over 500 bps next fiscal

Indian bond market issuances exceeded $105 billion, $25 billion new equity issued in FY24 - Shri Pramod Rao, ED, SEBI

One third of Nifty 100 companies hire thousands of young talent on apna.co


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020